1,791 Shares in Glaukos Co. (NYSE:GKOS) Purchased by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC acquired a new stake in Glaukos Co. (NYSE:GKOS) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,791 shares of the medical instruments supplier’s stock, valued at approximately $212,000.

A number of other hedge funds also recently bought and sold shares of the business. Sei Investments Co. grew its position in shares of Glaukos by 51.6% in the second quarter. Sei Investments Co. now owns 108,546 shares of the medical instruments supplier’s stock valued at $12,847,000 after purchasing an additional 36,933 shares in the last quarter. Brighton Jones LLC acquired a new position in Glaukos during the second quarter worth $208,000. Intech Investment Management LLC purchased a new stake in Glaukos in the 2nd quarter valued at $1,346,000. Seven Eight Capital LP acquired a new stake in shares of Glaukos in the 2nd quarter worth $1,940,000. Finally, Wealth Alliance purchased a new position in shares of Glaukos during the 2nd quarter worth $246,000. Institutional investors and hedge funds own 99.04% of the company’s stock.

Insider Transactions at Glaukos

In related news, Director Aimee S. Weisner sold 25,000 shares of the business’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the transaction, the director now directly owns 30,119 shares of the company’s stock, valued at approximately $3,614,280. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Glaukos news, Director Marc Stapley sold 6,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total value of $787,062.50. Following the sale, the director now directly owns 34,076 shares of the company’s stock, valued at approximately $4,291,190.68. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Aimee S. Weisner sold 25,000 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the completion of the sale, the director now owns 30,119 shares in the company, valued at $3,614,280. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 41,500 shares of company stock valued at $5,099,000. 6.40% of the stock is currently owned by company insiders.

Glaukos Stock Performance

NYSE GKOS opened at $127.75 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.48 and a quick ratio of 4.67. The company has a market cap of $6.43 billion, a P/E ratio of -44.36 and a beta of 1.03. The stock has a 50-day moving average of $125.02 and a two-hundred day moving average of $112.28. Glaukos Co. has a 1-year low of $59.22 and a 1-year high of $136.60.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting the consensus estimate of ($0.52). The firm had revenue of $95.70 million for the quarter, compared to the consensus estimate of $88.86 million. Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The firm’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.55) EPS. As a group, analysts anticipate that Glaukos Co. will post -2.18 EPS for the current year.

Wall Street Analyst Weigh In

GKOS has been the subject of a number of analyst reports. Truist Financial reissued a “buy” rating and issued a $145.00 price objective (up previously from $141.00) on shares of Glaukos in a report on Thursday, August 1st. Wells Fargo & Company raised their price target on shares of Glaukos from $120.00 to $135.00 and gave the stock an “overweight” rating in a report on Thursday, August 1st. StockNews.com lowered shares of Glaukos from a “hold” rating to a “sell” rating in a research report on Friday, August 30th. Piper Sandler increased their price objective on Glaukos from $110.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. Finally, Stifel Nicolaus lifted their target price on Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat.com, Glaukos currently has a consensus rating of “Moderate Buy” and a consensus target price of $129.82.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.